• Home
• Partneringtools
• Reports

• Products
• Due Diligence
• Consulting

• In-licensing
• Out-licensing
• Companies

• Articles
• Events
• Outsourcing

• Jobs
• Forums
• Newsletter

Pharmalicensing Ltd
is a division of

— BERLIN, May 14

BERLIN, May 14 /PRNewswire/ -- Bundesverband der Pharmazeutischen Industrie e.V. (BPI) puts a strong focus on Europe, in order to promote the interests of German pharmaceutical companies at European level. Dr Bernd Wegener, chairman of BPI: "We dedicate experts and funds to creating our own basis for representing our membership." Dr Wegener continues: "The interests of European pharmaceutical companies and especially of small and mid-sized enterprises are not given enough consideration in the work of EFPIA (European Federation of Pharmaceutical Industries and Associations)."

The BPI chairman misses a clear-cut European industry policy:

"Mainly the change of EFPIA from an organisation of associations into an organisation of associations and companies has also brought changes in interest representation in the political arena - to the disadvantage of the interests of the European pharma industry which is primarily characterised by small and mid-sized structures."

As a logical consequence, BPI decided to leave EFPIA today. In the BPI's activities in Brussels the emphasis is now on pharma companies with a strong commitment to Europe as an industry location, because - unlike other industries - these businesses are currently not adequately represented.

BPI set out on a new path with the opening of its own Brussels office in early 2008, for an effective representation of member companies. This makes BPI the first German pharma association with a Brussels office of this kind, for a presence at European level.

Dr Wegener: "Our Brussels office ensures that BPI activities in Germany and in Europe go hand in hand, with a good information flow and answers in political issues for all BPI members. In cooperation with our member companies, our Brussels office has already become well established. Important contacts have been built up with European bodies and decision-makers. In the future, the voice of pharma companies with a European commitment will be much stronger in Brussels."

With over 50 years of experience in drug research, development, authorisation, manufacture and marketing, Bundesverband der Pharmazeutischen Industrie e. V. (BPI) covers the wide range of pharmaceutical industry activities at national and international levels. The membership of BPI includes over 260 enterprises with some 72,000 staff: Classic pharma­ceutical companies, businesses from biotechnology, phytopharmacy and homeopathy/ anthroposophy as well as pharma service providers.

Contact: Wolfgang Strassmeir, phone +49-30-27909-131, wstrassmeir@bpi.de

Industry news: Pharmalicensing provides comprehensive industry coverage.

Products:	Partnering Consulting	Partnering Search	Company Profiling	Comparision	Partneringtools	Reports
In-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Out-licensing:	Latest records	Industry Sector	Therapeutic Target	Search	Profile your company	Pharma partnering
Companies:	Profiled companies	Industry Sector	Therapeutic Target	Geographic Location	Search	Add your company
Reports:	Biotechnology	Business Development	Management	Market & Sales	Medical Devices	Pharmaceuticals
Jobs:	Pharmaceutical jobs	Browse jobs	Search for jobs	Create your CV	Employer profiles	Post your jobs
Forums:	Talk to an expert	Industry Gossip	Business Development	What's new	Reports	Outsourcing
News:	Deals & Alliances	Development	Financial Results	Financings	Intellectual Property	Regulatory
Events:	Pharma events	Calendar	Organizers	Featured events	Search	Add your event
Articles:	Business Development	Technologies	Events	Legal and regulatory	Therapeutic	Post your article
Deals:	Industry Sector	Therapeutic Target	Deals Date	Search	Reports	Company releases
About us:	Our Audience	Case Studies	Newsletter	Careers	FAQ	Contact us